ARTICLE | Emerging Company Profile
Biotheus: fully-integrated mAb platform for optimized fast-follower products
China-based Biotheus goes from discovery to IND submission in about two years
September 27, 2023 12:20 AM UTC
Its fully-integrated mAb platform, from discovery to CMC manufacturing, has allowed Biotheus to bring multiple antibody programs into the clinic since its founding five years ago. The company is seeking partners to take over some of the programs in its expanding cancer pipeline, with BioNTech being the most recent to do so.
On July 20, Biotheus Inc. announced a deal granting BioNTech SE (NASDAQ:BNTX) options to a preclinical bispecific antibody and a clinical mAb...